JACKSONVILLE, Fla.—Johnson & Johnson Vision said Wednesday that the Food and Drug Administration (FDA) has approved Acuvue Abiliti Overnight Therapeutic Lenses. This new lens is the first and only FDA approved orthokeratology (ortho-k) contact lens for the management of myopia, according to the announcement. The lens, expected to launch by the end of 2021, will be available in sphere and toric designs to correct various combinations of corneal shapes and refractive errors. he FDA approval of Abiliti Overnight stems from the collaboration between J&J Vision and Menicon to bring forward therapeutic contact lenses for the treatment of myopia under the Acuvue Abiliti Brand, which J&J Vision said is a “new brand for future products and services to help parents and eyecare professionals address the progression of myopia in children.” Read More